PATENT CLAIM ANALYSIS

Application Number: 15753790
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-09
Patent Classification: ["514", "255030"]

Abstract:
This invention is related to the field of PCSK9 biology and the composition and methods of use of small organic compounds as ligands for modulation of PCSK9 biological activity. In particular, the invention provides compositions of small organic compounds that modulate circulating levels of low density lipoproteins by altering the conformation of the protein PCSK9. Binding these small organic compound ligands to PCSK9 alters the conformation of the protein, modifying the interaction between PCSK9 and an endogenous low density lipoprotein receptor, and can lead to reduced or increased levels of circulating LDL-cholesterol. High LDL-cholesterol levels are associated with increased risk for heart disease. Low LDL-cholesterol levels may be problematic in other conditions, such as liver dysfunction; thus, there is also utility for small organic compound ligands that can raise LDL levels.

Claim (Index 12):
A method for treating hypercholesterolemia in a mammal by and administering a pharmaceutical composition of a small organic compound of  claim 1  to said mammal.

Metadata:
- Claim Count in Document: 7.0
- Percentile: 88.0
- Lexical Diversity: 1.75309
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15505017', '14825700', '14767126', '15558491', '14421778']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7939965764974659
- 35 USC 102 Novelty (BERT): 0.586667673223913
- Combined Prediction Score: 0.7732636861701107
- Mean Citation Score: 357.37668
- Max Citation Score: 545.69147
- Similarity Product: 392.4356831584823

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test